Abstract
Stroke is a major cause of morbidity and mortality and follows heart disease and cancer as the third leading cause of death in Western societies [1]. Despite many advances in stroke research and pharmacotherapy, clinical treatment of this debilitating disorder is still inadequate. Recent findings from several laboratories have identified the endocannabinoid signaling pathway, comprised of the endocannabinoid agonist anandamide and its pharmacological targets, CB1 and CB2 cannabinoid receptors and associated anandamide receptors, as a physiological system with capacity to mitigate cardiovascular and cerebrovascular disorders through neuronal and endothelial actions. Variability in experimental stroke models and modes of outcome evaluation, however, have provoked controversy regarding the precise roles of endocannabinoid signals in mediating neural and/or vascular protection versus neurovascular damage. Clinical trials of the CB1 antagonist rimonabant demonstrate that modulation of endocannabinoid signaling during metabolic regulation of vascular disorders can significantly impact clinical outcomes, thus providing strong argument for therapeutic utility of endocannabinoids and/or cannabinoid receptors as targets for therapeutic intervention in cases of stroke and associated vascular disorders. The purpose of this review is to provide updated information from basic science and clinical perspectives on endocannabinoid ligands and their effects in the pathophysiologic genesis of stroke. Particular emphasis will be placed on the endocannabinoids anandamide and 2-arachidonylglycerol and CB1 receptor-mediated mechanisms in the neurovascular unit during stroke pathogenesis. Deficiencies in our knowledge of endocannabinoids in the etiology and pathogenesis of stroke, caveats and limitations of existing studies, and future directions for investigation will be addressed.
Keywords: 2-arachidonylglycerol, anandamide, CB1 receptor, endocannabinoid, ischemia, matrix metalloproteinase, stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Volume: 5 Issue: 4
Author(s): Somnath Mukhopadhyay and David A. Tulis
Affiliation:
Keywords: 2-arachidonylglycerol, anandamide, CB1 receptor, endocannabinoid, ischemia, matrix metalloproteinase, stroke
Abstract: Stroke is a major cause of morbidity and mortality and follows heart disease and cancer as the third leading cause of death in Western societies [1]. Despite many advances in stroke research and pharmacotherapy, clinical treatment of this debilitating disorder is still inadequate. Recent findings from several laboratories have identified the endocannabinoid signaling pathway, comprised of the endocannabinoid agonist anandamide and its pharmacological targets, CB1 and CB2 cannabinoid receptors and associated anandamide receptors, as a physiological system with capacity to mitigate cardiovascular and cerebrovascular disorders through neuronal and endothelial actions. Variability in experimental stroke models and modes of outcome evaluation, however, have provoked controversy regarding the precise roles of endocannabinoid signals in mediating neural and/or vascular protection versus neurovascular damage. Clinical trials of the CB1 antagonist rimonabant demonstrate that modulation of endocannabinoid signaling during metabolic regulation of vascular disorders can significantly impact clinical outcomes, thus providing strong argument for therapeutic utility of endocannabinoids and/or cannabinoid receptors as targets for therapeutic intervention in cases of stroke and associated vascular disorders. The purpose of this review is to provide updated information from basic science and clinical perspectives on endocannabinoid ligands and their effects in the pathophysiologic genesis of stroke. Particular emphasis will be placed on the endocannabinoids anandamide and 2-arachidonylglycerol and CB1 receptor-mediated mechanisms in the neurovascular unit during stroke pathogenesis. Deficiencies in our knowledge of endocannabinoids in the etiology and pathogenesis of stroke, caveats and limitations of existing studies, and future directions for investigation will be addressed.
Export Options
About this article
Cite this article as:
Mukhopadhyay Somnath and Tulis A. David, Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (4) . https://dx.doi.org/10.2174/187152507782109917
DOI https://dx.doi.org/10.2174/187152507782109917 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol Targets in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets A New Validated HPLC-DAD Method for Estimation of Solasodine from Solanum nigrum Linn. Extracts and Formulations
The Natural Products Journal Preface (Hot Topic: Medicinal Strategies in the Treatment of Obesity Guest Editor: Akio Inui)
Current Medicinal Chemistry - Central Nervous System Agents Coenzyme Q10 and Neurological Diseases: An Update
Letters in Drug Design & Discovery The Future of Induced Pluripotent Stem Cells for Cardiac Therapy and Drug Development
Current Pharmaceutical Design Gene Polymorphism of Angiotensin II Type 1 and Type 2 Receptors
Current Pharmaceutical Design The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Natural Products as Anti-glycation Agents: Possible Therapeutic Potential for Diabetic Complications
Current Diabetes Reviews The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential
Current Medicinal Chemistry Advancement in Microsponge Drug Delivery System: Preparation Methods, Patents and Commercial Utility
Recent Patents on Drug Delivery & Formulation The Effect of Ethyl Acetate Extract of Pomelo Mix on Systemic Exposure of Verapamil in Rabbits
Drug Metabolism Letters Alzheimer's Disease Prevention and Use of Traditional Plant Medicines
Letters in Drug Design & Discovery Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy Bispidine as a Privileged Scaffold
Current Topics in Medicinal Chemistry Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile
Current Pharmaceutical Design Flavonoids and Chagas' Disease: The Story So Far!
Current Topics in Medicinal Chemistry Antioxidant, Anti-Inflammatory and Anticancer Activities of the Methanolic Extract of Thottea siliquosa: An <i>In Vitro</i> and <i>In Silico</i> Study
Recent Patents on Anti-Cancer Drug Discovery Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design